DEALER-MANAGER AGREEMENTDealer-Manager Agreement • December 9th, 2024 • Cytosorbents Corp • Surgical & medical instruments & apparatus • New York
The following will confirm our agreement relating to the proposed offering (the “Offering”) to be undertaken by CytoSorbents Corporation, a Delaware corporation (the “Company”), pursuant to which the Company will dividend at no cost to holders of record of its common stock, par value $0.001 per share (“Common Stock”) and certain eligible warrantholders, non-transferable subscription right warrants (the “Subscription Rights”) as set forth in the Company’s Prospectus Supplement to be filed on or about December 9, 2024 (the “Prospectus Supplement”) to the Company’s Form S-3 shelf registration statement (File No. 333-281062) declared effective by the U.S. Securities and Exchange Commission (the “Commission”) on September 30, 2024 (the “Registration Statement”), to subscribe for and purchase up to 6,250,000 units (the “Units”) at a subscription price equal to $1.00 (the “Unit Subscription Price”). Each Unit will consist of one share of Common Stock, one Series A right warrant to purchase on
